In this follow-up study of the multicenter ‘HOPE ECD-DBD’ randomized controlled trial[1], Czigany et al assessed the long-term effects of end-ischemic hypothermic oxygenated machine perfusion (HOPE) using Liver Assist in extended criteria donation after brain death (ECD-DBD) liver transplantion. With a median follow-up of 48 months, HOPE-treatment resulted in significantly improved long-term graft survival (p=0.029), fewer late-onset[2] major complications (Clavien-Dindo grade ≥ 3: 43% vs 85%; p=0.009) and reduced morbidity (CCI: 23 [IQR 0-37]) vs 46 [IQR 34-95], p=0.003) compared to SCS alone. Also, multvariate analysis revealed that HOPE-treatment was the only variable with a significant and independent correlation with a reduced risk of developing late-onset major complications (Clavien-Dindo grade ≥ 3: OR 0.15; p=0.03 ). This long-term follow-up demonstrates that the beneficial effects of HOPE extend beyond the early post-operative phase, with a sustained reduction of late-onset complications and superior long-term graft survival.
“HOPE is a simple, practical, and cost-efficient back-to-base dynamic ex vivo preservation technology”
Czigany et al 2024
“this trial provides first-time evidence that HOPE, in comparison to SCS, significantly improves long-term post-transplant outcomes in ECD LT”
Czigany et al 2024
Hepatol Commun | 2024 | doi: 10.1097/HC9.0000000000000376
[1] Czigany et al 2021 – Hypothermic Oxygenated Machine Perfusion Reduces Early Allograft Injury and Improves Post-transplant Outcomes in Extended Criteria Donation Liver Transplantation From Donation After Brain Death: Results From a Multicenter Randomized Controlled Trial (HOPE ECD-DBD)
[2] Complications occurring later than 6 months after LT
